OLMA
Olema Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$7.11
+8.05%Next report
Analyst consensus
- Next report date
- Nov 9, 2026
- EPS estimate
- -$0.60
- Revenue estimate
- $1.3M
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.61
- EPS estimate
- -$0.55
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +2.8%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $43
- PT range
- $30 – $59
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.55 | -$0.61 | Miss -10.62% | — |
| May 12, 2026 | -$0.52 | -$0.52 | In line | — |
| Mar 16, 2026 | -$0.51 | -$0.50 | Beat 2.73% | — |
| Mar 18, 2025 | -$0.63 | -$0.51 | Beat 19.05% | — |
| May 8, 2024 | -$0.53 | -$0.56 | Miss -5.66% | — |
| Mar 11, 2024 | -$0.49 | -$0.49 | In line | $1.9M |
| Mar 9, 2023 | -$0.65 | -$0.65 | In line | — |
| Feb 28, 2022 | -$0.51 | -$0.54 | Miss -5.88% | — |
| Nov 10, 2021 | -$0.47 | -$0.45 | Beat 4.26% | — |
| Aug 10, 2021 | -$0.39 | -$0.42 | Miss -7.69% | — |
| Mar 17, 2021 | -$0.18 | -$0.50 | Miss -177.78% | — |
| Nov 19, 2020 | — | -$0.17 | — | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 9, 2026